Loading...
Market
Market share of YORVIPATH in US hypoparathyroidism treatment market by end of 2024?
2
Resolution / Starting Odds
0-25% • 25%
25-50% • 25%
50-75% • 25%
Above 75% • 25%
Market share data from healthcare market research firms such as IQVIA or GlobalData
Story
FDA Approves Ascendis Pharma's YORVIPATH, Stock Surges 11.8% Premarket
Aug 12, 2024, 11:53 AM
The U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma's YORVIPATH® (Palopegteriparatide) as the first and only treatment for hypoparathyroidism in adults. This approval marks a significant milestone as it fills the gap left by Takeda's withdrawal of its treatment for the same condition. The announcement has led to a notable increase in Ascendis Pharma's stock, which surged over 11.8% in premarket trading. Hypoparathyroidism is a rare hormone disorder, and YORVIPATH® will now be the only approved treatment available in the U.S. for this condition.
View original story
Similar markets
Ascendis Pharma • 25%
Takeda • 25%
Another existing company • 25%
A new entrant • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% market share • 33%
20%-40% market share • 34%
More than 40% market share • 33%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%